title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Data analysis | REGRESSION | The survey analysis was performed using StataMP (version 17.0). Longitudinal fixed effects logistic or linear regression models with robust standard errors to account for clustering at the level of the administrative cell were used to assess changes in children’s milk and ASF consumption and fathers’ nutrition-related ... | PMC10081762 | |
Results | Of the 151 fathers enrolled in the study, two were lost to follow-up. Therefore, the analysis includes 149 fathers who completed surveys at baseline and endline. | PMC10081762 | ||
Participant characteristics | Fathers who participated in the surveys lived in households that had received a cow 5.8 years ago on average ( | PMC10081762 | ||
Father and household characteristics at baseline (N = 149). | FGD participants’ mean age in years was 36.6 for mothers and 40.5 for fathers. FGD participants were from households with an average of two children under 5 years of age. Each household owned one milking cow from the Girinka program. IDIs with CEHO were conducted with four male and two female CEHOs. Their mean age in y... | PMC10081762 | ||
Survey results | PMC10081762 | |||
Changes in children’s ASF consumption | The ASFs most frequently consumed by children under 5 years were milk, fish, eggs, and beef ( | PMC10081762 | ||
Changes in fathers’ knowledge and awareness of ASFs | Fathers’ mean ASF knowledge score increased from baseline to endline (mean difference of 1.2 out of 4 items, | PMC10081762 | ||
Changes in fathers’ supportive actions for children’s milk and other ASF consumption and household decision-making about milk use | The majority of fathers offered one supportive action related to their children’s milk consumption, but the percentage of fathers who offered two or more supportive actions increased from baseline to endline (19.5% to 31.5%, | PMC10081762 | ||
Fathers’ exposure to the intervention | Nearly all fathers (98%) had heard about ASFs through community-based meetings where milk or other ASFs were discussed in the last 4 months ( | PMC10081762 | ||
Fathers’ exposure to the intervention (N = 149). | ASF, animal source food; CEHO, community extension and health officer; CHW, community health worker; SBCC, social and behavior change communicationThree-quarters of fathers reported that they received text messages about milk or other ASFs. More than 95% of fathers who participated in meetings or received text messages... | PMC10081762 | ||
Qualitative results | Several key themes were identified in the FGD and IDI data. They are described here, and illustrative quotations are shown in | PMC10081762 | ||
Key themes and illustrative quotations from qualitative data collected from fathers, mothers, model fathers, and CEHOs. | PMC10081762 | |||
Selection of less expensive ASFs to overcome the financial barrier to ASF consumption | All fathers in FGDs mentioned that lack of financial means to purchase ASFs, especially flesh foods, is the main barrier to consumption of ASFs in their household. However, with encouragement from model fathers and reminders through text messages, fathers explained that they tried their best to find more affordable ASF... | PMC10081762 | ||
Increase in fathers’ knowledge of ASFs | Most fathers in FGDs discussed the relevance of the messages received from model fathers, which supported improving their knowledge on the appropriate age to introduce ASFs to young children. Fathers in both districts expressed that the knowledge they gained to improve household nutrition was the most important aspect ... | PMC10081762 | ||
Improvements in joint decision-making by fathers and mothers about use of home-produced milk | SAID | Fathers said the second most important aspect of the program was improvements in joint decision-making with their wives about household milk use. The majority of fathers in the FGDs explained that they were inspired by the model fathers to jointly discuss with their wives how much cow’s milk from daily milking to keep ... | PMC10081762 | |
Importance of monthly community-based meetings | ’ | SAID | Fathers liked the monthly meetings that were facilitated by the model fathers because they encouraged the family to eat and buy ASFs that were accessible to them. They were inspired by the model fathers’ actions as examples in their own communities. Most mothers stated that they noticed positive changes in their husban... | PMC10081762 |
SBCC materials were acceptable and provided clear actions and timely reminders for fathers | SAID | Almost all fathers in FGDs in both districts said that they related to the messages and images on the leaflet and poster shared by model fathers during monthly meetings. They found the images inspirational and appreciated that they showed fathers happy and working with their wives. Receiving text messages helped to rei... | PMC10081762 | |
Recommendations for improved implementation | Model fathers requested additional training on facilitation skills and suggested that follow-up sessions at household level would provide the opportunity to observe men putting the messages learned into action and would highlight where more support is needed. CEHOs and model fathers suggested that future interventions ... | PMC10081762 | ||
Discussion | hearing ASF | SECONDARY | This study found that an SBCC intervention encouraging fathers in livestock-keeping households to support child nutrition increased the percentage of children who more frequently consumed ASFs, specifically milk, eggs, and beef. ASFs are important sources of protein, iron, zinc, vitamin A, and other micronutrients [The... | PMC10081762 |
Supporting information | PMC10081762 | |||
Messages and images for engaging fathers to support child nutrition in Rwanda. | (DOCX)Click here for additional data file. | PMC10081762 | ||
Inclusivity in global research checklist. | (DOCX)Click here for additional data file. | PMC10081762 | ||
Sources of ASFs consumed by children in the past 7 days. | RTI, EDWARDS | (DOCX)Click here for additional data file.We would like to thank Verena Ruzibuka and Silver Karumba at the USAID Rwanda Mission, Anita Asiimwe at the National Child Development Agency, Théogène Rutagwenda at the Ministry of Agriculture, and Jesse Routte at Three Stones International for their support of this project. W... | PMC10081762 | |
References | PMC10081762 | |||
Subject terms | mCRC | METASTATIC COLORECTAL CANCER | Bevacizumab (Bev) plus chemotherapy is a standard first-line treatment in metastatic colorectal cancer (mCRC), however to date no predictive factors of response have been identified. Results of our previous analysis on patients enrolled in a randomized prospective phase III multicenter study (ITACa study) showed a pred... | PMC10412588 |
Introduction | cancers, CRC, cancer death, cancer, Colorectal cancer | CANCERS, CANCER, METASTATIC DISEASE, MALIGNANCIES, COLORECTAL CANCER | Colorectal cancer (CRC) is one of the most common malignancies, globally repre-senting the fourth most diagnosed cancer in the world, third in incidence in men and second in women. CRC is the third leading cause of cancer death in the world, consider-ing both men and women globallyIn about 25% of cases, it occurs as a ... | PMC10412588 |
Results | ONCOLOGY | From January 2016 to October 2019, 182 patients were enrolled into this trial. Thirteen patients were excluded from the analysis due to eligibility criteria violation. Table Patient characteristics.ECOG PS, Eastern Cooperative Oncology Group Performance Status.Genotype frequencies. | PMC10412588 | |
Association between polymorphisms and clinical outcomes | We evaluated the correlation between PFS and PFS and OS in relation to polymorphisms.With regard to OS, no statistically significant difference was observed between polymorphism genotypes (Table We also investigated | PMC10412588 | ||
Discussion | failure of the “candidate SNP, tumor | TUMOR, SECONDARY, TUMOR ANGIOGENESIS | In our previous analysis, two haplotypes based on Homozygosity in The analyses performed did not confirm what was found in the previous study, in particular patients bearing PFS and OS in relation to haplotypes.H1/H1, Haplo1/Haplo1; H2/H2, Haplo2/Haplo2; H1/H1 + H2/H2, Haplo1/Haplo1 + Haplo2/Haplo2.*Ajusted HR and Kapl... | PMC10412588 |
Materials and methods | PMC10412588 | |||
Patients and treatment | toxicity, PD, NRAS | DISEASE PROGRESSION, RECURRENCE, METASTATIC DISEASE, ONCOLOGY, RECTAL CANCER | This is a prospective non-pharmacological trial aimed at validating This study involved 182 patients with mCRC treated with first-line chemotherapy plus Bev at the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” in Meldola. Patients ≥ 18 years of age, with histologically confirmed mCRC, one or m... | PMC10412588 |
Statistical analysis | death | REGRESSION | Based on the results obtained from the ITACa study, we assumed a prevalence of the haplotype to be validated (homozygosity in Patient characteristics were summarized using the median and range for the contin-uous variables and frequencies and percentages for the categorical variables. PFS was de-fined as the time betwe... | PMC10412588 |
Ethical approval | The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Ethics Committee of IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy (reference number IRSTB038 and date of approval 08/07/2015). | PMC10412588 | ||
Consent for publication | Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper. | PMC10412588 | ||
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-023-40220-7. | PMC10412588 | ||
Acknowledgements | tumors | TUMORS | This work was partly supported thanks to the contribution of Ricerca Corrente by the Italian Ministry of Health within the research line "Precision, gender and ethnicity-based medicine and geroscience: genetic-molecular mechanisms in the development, characterization and treatment of tumors. | PMC10412588 |
Author contributions | Conceptualization, A.P. and P.U.; methodology, I.A.; validation, G.M., I.A., A.P, P.U.; formal analysis, I.A.; investigation, G.M., F.R., G.B., M.U., M.C., C.M., S.A.D.; resources, A.P., G.B., L.M., F.G.S., S.A.D., C.G., G.G., G.L.F.; data curation, G.M., A.P., P.U.; writing-original draft preparation, G.M, I.A, A.P, P... | PMC10412588 | ||
Data availability | The data supporting the fndings of this study could be obtained from the corresponding author. | PMC10412588 | ||
Competing interests | The authors declare no competing interests. | PMC10412588 | ||
References | PMC10412588 | |||
Subject terms | HBV-related ACLF, non-cirrhotic, cirrhosis, muscle index (PMI)-based nomogram for cirrhosis, acute-on-chronic liver failure | CIRRHOSIS | There is a lack of scoring system to predict the occurrence of cirrhosis in individuals with acute-on-chronic liver failure (ACLF) in the absence of cirrhosis. The goal of this study was to develop a psoas muscle index (PMI)-based nomogram for cirrhosis risk in non-cirrhotic patients with HBV-related ACLF. We included ... | PMC10692120 |
Introduction | loss of skeletal muscle mass, Acute-on-chronic liver failure, skeletal muscle mass, liver decompensation, sarcopenia, cirrhosisSarcopenia, malnutrition, CLD, whole-body skeletal muscle mass | LIVER DECOMPENSATION, SARCOPENIA, LOSS OF SKELETAL MUSCLE MASS, MALNUTRITION, CLD, CHRONIC LIVER DISEASE | Acute-on-chronic liver failure (ACLF) is a condition characterized by acute and severe liver decompensation in patients with underlying chronic liver disease (CLD), with or without cirrhosisSarcopenia, which refers to the loss of skeletal muscle mass and function, is a major component of the malnutrition in patients su... | PMC10692120 |
Methods | PMC10692120 | |||
Patients | cancers, death, cirrhosis, tuberculosis, neuromuscular disease, consumptive diseases, HCC, malnutrition | CANCERS, LIVER, CIRRHOSIS, TUBERCULOSIS, NEUROMUSCULAR DISEASE, HYPERTHYROIDISM, HEPATOCELLULAR CARCINOMA, MALNUTRITION | Patients with HBV-ACLF who were admitted at the First Affiliated Hospital of Chongqing Medical University between January 2012 and August 2021 were included in this study retrospectively. The following were the inclusion requirements: (1) 18 years and over; (2) hepatitis B surface antigen (HBsAg) and/or HBV DNA positiv... | PMC10692120 |
Clinical data | cirrhosis | CIRRHOSIS, PORTAL HYPERTENSION | Demographic data (gender, age, height, and weight), laboratory findings (routine blood, liver function, renal function, electrolytes, coagulation indices, and HBV virologic markers), and antiviral nucleoside analogue usage for HBV throughout follow-up were all clinical data that we gathered. We calculated the prognosti... | PMC10692120 |
Evaluation of Psoas Muscle Index | Within 2 weeks of the diagnosis of ACLF, all enrolled patients underwent abdominal CT scans manufactured by Siemens AG, Germany. Two imaging specialists independently evaluated the lumbar muscle area (cm | PMC10692120 | ||
Statistical analysis | cirrhosis | REGRESSION, CIRRHOSIS | MedCalc software (version 20.1.0), IBM SPSS Statistics (version 22.0), and R software (version 4.1.2) were used for statistical analyses. The study comprised 274 patients, with 183 randomly allocated to the training cohort to generate the prediction model and the remaining 91 patients assigned to the validation group t... | PMC10692120 |
Results | PMC10692120 | |||
Patients' baseline characteristics | cirrhosis | CIRRHOSIS | A total of 274 HBV-ACLF patients without cirrhosis were included in this study. Patients' mean PMI was 6.4 ± 1.5 cmTwo groups of 274 patients, one for training (n = 183) and the other for validation (n = 91), were randomly allocated. Regarding baseline characteristics, the two groups were similar (Table | PMC10692120 |
Factors involved in progression to cirrhosis | TB, cirrhosis, non-cirrhosis, end-stage liver disease | REGRESSION, CIRRHOSIS | In the training cohort, 81 (44.3%) patients developed cirrhosis within 360 days, and 102 (55.7%) patients were not affected with cirrhosis. Table Comparison of the baseline characteristics between cirrhosis and non-cirrhosis groups in the training cohort.SD, standard deviation; IQR, interquartile range; BMI, body mass ... | PMC10692120 |
Construction of PMI-based nomogram for long-term progression to cirrhosis | cirrhosis | CIRRHOSIS | We then developed a nomogram using the four independent predictors mentioned above, namely PMI, age, NLR, and INR (Fig. The nomogram used to predict the risk of cirrhosis in the training cohort. PMI, psoas muscle index; NLR, neutrophil-to-lymphocyte ratio; INR, International normalized ratio. | PMC10692120 |
Validation of PMI-based nomogram | The nomogram outperformed the MELD and MELD-Na scores in the training group, having significantly higher AUROCs [0.812 (95% CI 0.747–0.866), 0.702 (95% CI 0.630–0.768), and 0.727 (95% CI 0.656–0.790), respectively, both P < 0.05], demonstrating superior discriminatory capacity (Fig. Area under the receiver operating ch... | PMC10692120 | ||
Discussion | death, non-cirrhotic ACLF, end-stage liver disease, inflammation, cirrhosis, sarcopenia, abrupt hepatic deterioration, liver disease, organ failure, NAFLD, hepatic fibrosis, CLD, cirrhosis in non-cirrhotic HBV-ACLF | INFLAMMATION, CIRRHOSIS, SARCOPENIA, LIVER FIBROSIS, LIVER DISEASE, MALNUTRITION, OXIDATIVE STRESS, CLD | To our knowledge, this is the first research to exam how PMI could affect non-cirrhotic HBV-ACLF patients' long-term (1 year) progression to cirrhosis. Our research suggests that a higher PMI at L3 may prevent the development of cirrhosis. We have also developed a PMI-based nomogram for cirrhosis risk stratification in... | PMC10692120 |
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-023-47463-4. | PMC10692120 | ||
Author contributions | J.B. | J.B. and Y.L.: design and conception. J.B.: recruiting patients. J.B., J.G., and F.P.: information gathering. J.B., M.X., and X.S.: data analysis. J.B. and X.S.: draft creation. J.B., M.X., X.S., and Y.L.: editing and refining the manuscript. The final text was reviewed and approved by all authors. | PMC10692120 | |
Funding | This study was supported by National Natural Science Foundation of China (No. 82300704) and the Postdoctoral Science Foundation of Chongqing, China (No. CSTB2023NSCQ-BHX0181). | PMC10692120 | ||
Data availability | The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. | PMC10692120 | ||
Competing interests | The authors declare no competing interests. | PMC10692120 | ||
References | PMC10692120 | |||
Background | respiratory depression, pain, cardiovascular adverse | RESPIRATORY DEPRESSION | Propofol-based sedations are widely used in elderly patients for endoscopic retrograde cholangiopancreatography (ERCP) procedure, but respiratory depression and cardiovascular adverse events commonly occur. Magnesium administered intravenously can alleviate pain and decrease propofol requirements during surgery. We hyp... | PMC10326926 |
Methods | Eighty patients aged from 65 to 79 years who were scheduled for ERCP were enrolled. All patients were intravenously administered 0.1 µg/kg sufentanil as premedication. The patients were randomized to receive either intravenous magnesium sulfate 40 mg/kg (group M, | PMC10326926 | ||
Results | The total propofol consumption were reduced by 21.4% in the group M compared with the group N (151.2 ± 53.3 mg vs. 192.3 ± 72.1 mg, | PMC10326926 | ||
Conclusions | ADVERSE EVENTS | A single bolus of 40 mg/kg of intravenous magnesium can significantly reduce propofol consumption during ERCP, with higher sedation success and lower adverse events. | PMC10326926 | |
Trial Registration | ID UMIN000044737. Registered 02/07/2021. | PMC10326926 | ||
Keywords | PMC10326926 | |||
Background | respiratory depression, disorders of pancreaticobiliary pathologies | ADVERSE EVENTS, EVENTS, RESPIRATORY DEPRESSION | Endoscopic retrograde cholangiopancreatography (ERCP) is a common procedure employed to diagnose and treat disorders of pancreaticobiliary pathologies [Propofol is the most commonly used hypnotic agent in sedation during endoscopic procedures for its advantages of fast onset and quick recovery. However, propofol may ca... | PMC10326926 |
Methods | PMC10326926 | |||
Ethics | This was a prospective, randomized and double-blinded study performed in the endoscopic unit of People’s Hospital of Chongqing Banan District between August 13, 2021 and March 25, 2022. The protocol had been registered (UMIN000044737) in UMIN Clinical Trials Registry (UMIN-CTR). Ethical approval for the study (No. 011-... | PMC10326926 | ||
Inclusion and exclusion | hypoxemia, hypersensitivity, hypotension | ADVERSE EVENTS, LIVER DISEASES, HYPERSENSITIVITY, UNCONTROLLED HYPERTENSION | Adult patients of American Society of Anesthesiologists (ASA) physical status I through III aged between 65 and 79 years of either sex scheduled for ERCP under sedation were included in this study. Exclusion criteria were severe cardiac, lung, renal, neurological, or liver diseases, hypotension (systolic blood pressure... | PMC10326926 |
Randomization and blinding | Eligible patients were randomly assigned to either a magnesium sulfate group or a normal (0.9%) saline group at a ratio of 1:1 using a computer-generated sequence. Group assignments were placed into opaque, sealed, consecutively numbered envelopes by staff who was not involved in the trial. The envelopes were opened ju... | PMC10326926 | ||
Sedation protocol | The patients were fasted routinely for overnight, and received 5ml of oral 2% lidocaine hydrochloride mucilage and topical spray oropharyngeal anesthesia with 4% lidocaine as premedication 20 min prior to the start of the sedation. Then the patients were placed in prone position with their head on the right side and ad... | PMC10326926 | ||
Study endpoint | lethargy, bradycardia, arrhythmia, postoperative nausea and vomiting, pain, hypotension, PONV | ADVERSE EVENTS, SECONDARY, RESPIRATORY DEPRESSION, ARRHYTHMIA | The primary outcome was total propofol consumption. The main secondary outcomes were: procedure time (defined as the time from the insertion of the endoscope to the extraction of the endoscope); sedation time (defined as the time from administration of propofol to the end of the procedure); the incidence of adverse eve... | PMC10326926 |
Data analysis | SD, pain | The sample size was calculated based on the primary outcome of this study, the total cumulative dose of propofol during ERCP procedure. A placebo-controlled pilot study of 20 patients showed the mean ± standard deviation (SD) of administered dose of propofol during procedure was 207.4 ± 73.7 mg. We anticipated a 20% di... | PMC10326926 | |
Results | renal failure, postoperative nausea and vomiting, SD, pain, PONV | RENAL FAILURE, RECRUITMENT | A total of eighty-four patients were enrolled initially in the present study. Of these, four patients were excluded due to severe renal failure (
Demographic characteristics and procedure detailsData are expressed as mean ± SD, or number of patients (percent). Group N, normal saline group; Group M, magnesium sulfate gr... | PMC10326926 |
Discussion | lethargy, biliary and pancreatic diseases, bradycardia, nausea or vomiting, arrhythmia, hypermagnesemia, eclampsia, brain injury, hypotension, respiratory depression | CARDIOPULMONARY DISEASES, ARRHYTHMIA, HYPERMAGNESEMIA, MYOCARDIAL ISCHEMIA, COMPLICATIONS, ECLAMPSIA, ADVERSE EFFECTS, RESPIRATORY DEPRESSION, PREECLAMPSIA | ERCP is a gold standard diagnostic and treatment method for patients with biliary and pancreatic diseases which are common in the elderly. Elders are often comorbid with cardiopulmonary diseases. Studies have shown that the high prevalence of cardiopulmonary complications may be associated with mortality, brain injury,... | PMC10326926 |
Conclusions | respiratory depression, pain | ADVERSE EVENTS, RESPIRATORY DEPRESSION | A single bolus of 40 mg/kg of intravenous magnesium can significantly reduce propofol requirements and decrease the incidence of respiratory depression and involuntary body movement. Furthermore, it alleviates the postprocedure pain and allows high patient satisfaction and lower adverse events. Therefore, magnesium cou... | PMC10326926 |
Acknowledgements | This study was conducted at People’s Hospital of Chongqing Banan District. We are extremely grateful to everyone who participated and cooperated in the surveys. | PMC10326926 | ||
Authors’ contributions | The study protocol was written by JC and JQW with support from the academic supervisory team of KQ, CHL, XLL and YC. Data collection and analysis was completed by JC, KQ, CHL and YC with support from XLL and JQW. The manuscript was written by JC, KQ, CHL, XLL, YC and JQW. The authors read and approved the final manuscr... | PMC10326926 | ||
Funding | No current funding sources for this study. | PMC10326926 | ||
Data availability | The de-identified data for individual participants underlying our results can be accessed with approval from the corresponding author 6 months after publication. The study protocol, statistical analyses, and clinical study report will also be available. | PMC10326926 | ||
Declarations | PMC10326926 | |||
Conflict of interest | All authors disclosed no financial relationships relevant to this publication. | PMC10326926 | ||
Ethics approval and consent to participate | The study was reviewed and approved by the Ethics Committee of People’s Hospital of Chongqing Banan District, Chongqing, China on 7th June 2021 and a favourable opinion was given on 10th August 2021 (No. 011-2021). The study was conducted according to the Declaration of Helsinki. Written informed consent was obtained f... | PMC10326926 | ||
Consent for publication | Not applicable. | PMC10326926 | ||
Competing interests | The authors declare no competing interests. | PMC10326926 | ||
References | PMC10326926 | |||
Keywords | FCC | DISORDER | Functional chronic constipation (FCC) is a disorder caused by low fiber consumption, lack of fluid intake, lack of mobility, or side effects of medications. The objective of this study was to compare the effects of laser acupuncture and the commonly used osmotic laxative, lactulose (as the control), both combined with ... | PMC9931839 |
Introduction | Organic constipation, Acupuncture, constipation, multifactorial disorder, improves bowel movement, constipation bowel, Constipation | AIDS, FUNCTIONAL CONSTIPATION, PATHOLOGY | Functional chronic constipation is a multifactorial disorder that is mostly related to socioeconomic status, low fiber consumption, and lack of adequate fluid intake [There are two types of constipation (functional and organic). Functional constipation (FC) presents after the neonatal period, is not associated with any... | PMC9931839 |
Patients and methods | seizures, constipation, defecation disorders, spina bifida, neurologic diseases, injuries, metabolic abnormalities | CARDIAC DISEASES, DIABETES MELLITUS, HIRSCHSPRUNG DISEASE, CEREBRAL PALSY, HYPOTHYROIDISM, NEUROLOGICAL DISORDERS | The study was performed according to the Declaration of Helsinki principles, and approval was obtained from the ethical committee of the National Institute of Laser Enhanced Sciences (N.I.L.E.S) review board (Approval code 17/164 2021). The study was done in the Institute Pediatric outpatient clinics at Cairo Universit... | PMC9931839 |
Evaluation and follow-up | The randomization was performed by a medical assistant, while the examiner and the operator were blinded about the randomization process. The operator who delivered the intervention of laser application was under the supervision of different examiners who do not know about the study, just following the treatment regime... | PMC9931839 | ||
Statistical analysis | The unpaired A sample size estimate was performed prior to the study using G*POWER statistical software (version 3.1.9.2; Germany). In order to detect a minimum difference of one in frequency between groups, approximately 40 subjects were required, with 20 subjects for each group at | PMC9931839 | ||
Author contribution | Marwa | Amany M. Abd El Azeem: collected patients and did the clinical work and statistic work.Prof. Jehan Alsharnoubi: revised manuscript and follow up patients.Prof. Marwa Abd El-Rahman: revised manuscript. | PMC9931839 | |
Funding | Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). | PMC9931839 | ||
Declarations | PMC9931839 | |||
Conflict of interest | The authors declare no competing interests. | PMC9931839 | ||
References | PMC9931839 | |||
Objective: | MGC | METASTATIC GASTRIC CANCER, GASTRIC CANCER | Paclitaxel (P) is a standard second-line chemotherapy in the treatment of advanced gastric cancer. This study compared the clinical outcome of a paclitaxel plus raltitrexed (RP) regimen as second-line treatment in metastatic gastric cancer (MGC) patients. | PMC10546090 |
Methods: | An open, randomized, multi-center phase II clinical trial was conducted involving 148 patients who were randomly assigned and treated with RP [raltitrexed (3 mg/m | PMC10546090 | ||
Results: | RP | PFS had a tendency to be prolonged with RP compared to P (2.7 months | PMC10546090 | |
Conclusions: | ascites | ASCITES | Second-line palliative chemotherapy with RP was shown to prolong the PFS and OS, especially among patients with ascites or peritoneal involvement, which warrants confirmation using larger sample studies. | PMC10546090 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.